Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Spiroxatrine is an antagonist of the serotonin (5-HT) receptor subtype 5-HT1A (Ki = 3 nM) and α2-adrenergic receptors (α2-ARs; Kis = 28, 1.3, and 1.8 nM for α2A, α2B, and α2C, respectively).1 It is selective for these receptors over 5-HT1D (Ki = 2 µM) and 5-HT1B at 10 µM. Spiroxatrine also induces calcium mobilization in CHO cells expressing the human nociception opioid peptide (NOP) receptor (EC50 = 323 nM).2 It inhibits decreases in mean arterial pressure induced by urapidil in anesthetized normotensive cats when administered at doses of 3 or 10 nmol/kg.3 Spiroxatrine (2.5 and 5 mg/kg) induces catalepsy and catatonia in rats.4 It enhances reductions in ethanol intake induced by fluoxetine in alcohol-preferring rats.5
WARNING This product is not for human or veterinary use.
1. Spiroxatrine derivatives towards 5-
2. Synthesis and structure-
3. Involvement of brain 5-
4. On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacologia 34(3), 233-241 (1974).
5. Spiroxatrine augments fluoxetine-